

# Masahiro Takada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5245565/publications.pdf>

Version: 2024-02-01

58  
papers

1,220  
citations

331259

21  
h-index

377514

34  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1691  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyoderma Gangrenosum after Breast Cancer Resection: A Less-invasive and Early Treatment Using the Skin around Ulcers. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2022, 10, e4111.	0.3	1
2	Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. <i>Breast Cancer</i> , 2022, 29, 796-807.	1.3	2
3	Usefulness and Prospects of Sentinel Lymph Node Biopsy for Patients With Breast Cancer Using the Medical Imaging Projection System. <i>Frontiers in Oncology</i> , 2021, 11, 674419.	1.3	7
4	Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. <i>Cancer Science</i> , 2021, 112, 3338-3348.	1.7	3
5	A Novel Real-time Navigation System for Lymphaticovenular Anastomosis Using Projection Mapping with Indocyanine Green Fluorescence. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2021, 9, e3758.	0.3	1
6	Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 74-84.	5.1	16
7	Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. <i>Communications Biology</i> , 2020, 3, 578.	2.0	20
8	Neoadjuvant treatment for HER2-positive breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 32-32.	0.4	44
9	The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. <i>Breast Cancer</i> , 2020, 27, 322-331.	1.3	47
10	The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12631-e12631.	0.8	0
11	Predicting the efficacy of nivolumab combined with radiation therapy by longitudinal liquid biopsy with artificial intelligence for patients with metastatic breast cancer (translational research of the Tj ETQq1 1 0.784314 rgBT/Overlock	0.8	0
12	Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 532-532.	0.8	0
13	Sentinel Lymph Node Mapping. , 2020, , 223-227.		0
14	Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial). , 2020, , .		1
15	Abstract P3-09-07: A multicenter phase Ib/II study for evaluating safety and efficacy of Nivolumab in combination with radiation therapy in patients with HER2-negative metastatic breast cancer (KBCRN-B-002 trial). , 2020, , .		0
16	Abstract P2-10-12: Relationship between predicted risks of carrying breast cancer susceptibility genes and the presence of germline variants in Japanese patients with primary breast cancer. , 2020, , .		0
17	Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial. , 2020, , .		0
18	Abstract P4-10-33: Alteration of the tumor immune microenvironment signatures by nivolumab combined with radiation therapy for patients with metastatic breast cancer (Translational Research) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		0

#	ARTICLE	IF	CITATIONS
19	The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a 5mm margin treated without boost irradiation. <i>Radiation Oncology</i> , 2019, 14, 121.	1.2	6
20	Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. <i>International Journal of Clinical Oncology</i> , 2019, 24, 608-613.	1.0	22
21	The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study. <i>Breast Disease</i> , 2018, 37, 185-190.	0.4	1
22	Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. <i>Scientific Reports</i> , 2018, 8, 786.	1.6	71
23	Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. <i>Scientific Reports</i> , 2018, 8, 14930.	1.6	62
24	Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 611-618.	1.1	25
25	Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 675-683.	1.1	9
26	Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. <i>Photoacoustics</i> , 2018, 11, 6-13.	4.4	28
27	Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. <i>Breast Cancer</i> , 2018, 25, 650-655.	1.3	21
28	Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array. <i>Scientific Reports</i> , 2017, 7, 41970.	1.6	198
29	Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. <i>Journal of Radiation Research</i> , 2017, 58, 79-85.	0.8	7
30	Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. <i>Journal of Biomedical Optics</i> , 2016, 21, 116009.	1.4	48
31	Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1169-1175.	0.5	5
32	Data Mining and Mathematical Model Development. , 2016, , 381-388.		0
33	A New Concept for Axillary Treatment of Primary Breast Cancer Using Indocyanine Green Fluorescence Imaging. , 2016, , 139-147.		0
34	Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer. <i>Annals of Oncology</i> , 2015, 26, vii78.	0.6	2
35	Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging. <i>PLoS ONE</i> , 2015, 10, e0139113.	1.1	53
36	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 709-722.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Abstract P1-02-01: Evaluation of second-generation photoacoustic mammography in detecting the breast cancer vasculature and hypoxic status; a preliminary study. , 2015, , .		2
38	Abstract P3-01-02: Clinical, anatomical and histological characteristics of breast lesions visualized by photoacoustic mammography; first clinical study in CK project. , 2015, , .		0
39	Development of Web Tools to Predict Axillary lymph Node Metastasis and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. International Journal of Biological Markers, 2014, 29, 372-379.	0.7	4
40	A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy. Breast Cancer, 2014, 21, 504-507.	1.3	15
41	Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. International Journal of Clinical Oncology, 2014, 19, 852-862.	1.0	24
42	Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Research and Treatment, 2014, 145, 143-153.	1.1	35
43	Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. , 2013, 2013, 3054-7.		9
44	Development of Photoacoustic Mammography for Detection of Breast Cancer. Nippon Laser Igakkaishi, 2013, 34, 24-29.	0.0	1
45	Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer. Breast Journal, 2012, 18, 535-541.	0.4	34
46	Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. BMC Medical Informatics and Decision Making, 2012, 12, 54.	1.5	36
47	Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique. Breast Cancer Research and Treatment, 2012, 134, 661-670.	1.1	18
48	Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast, 2012, 21, 40-45.	0.9	14
49	Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. European Journal of Cancer, 2011, 47, 2265-2272.	1.3	27
50	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Science, 2011, 102, 858-865.	1.7	44
51	Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer, 2011, 18, 64-67.	1.3	21
52	Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Clinical Therapeutics, 2010, 32, 311-326.	1.1	12
53	Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomedicine and Pharmacotherapy, 2009, 63, 703-706.	2.5	43
54	Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Research and Treatment, 2007, 104, 267-275.	1.1	67

#	ARTICLE	IF	CITATIONS
55	Natural killer cells in breast cancer cell growth and metastasis in SCID mice. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, S375-S379.	2.5	41
56	A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. <i>International Journal of Oncology</i> , 2004, 25, 397.	1.4	4
57	Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 2338-2343.	2.9	42
58	Current status of antibody therapy for breast cancer. <i>Breast Cancer</i> , 2004, 11, 10-14.	1.3	19